ICE Bioscience Posters

Download

In pharmaceutical development, early assessment of drug candidate safety is critical to mitigate post-market withdrawals and reduce risks. Approximately 75% of adverse drug reactions (ADRs) are dose-dependent (Type A), often linked to off-target interactions. To address this, we have introduced ICESTP SAFETYPANEL^TM 44, a product comprising 44 screening models de­signed to assess target safety across critical areas such as the central nervous system, cardiovascular system, metabolism, and immunity. This panel has already successfully screened over 700 different types of compounds. Building on this initial product, we have further developed two new products: ICESTP SAFETYPANEL^TM 77 and ICESTP SAFETYPANE^TM PLUS, as shown in Figure 1, which are cutting-edge functional safety assessment panels designed to revolutionise drug development. By evaluating the agonist or antagonist effects of compounds on these targets through functional activity screening, we assess compound safety and provide reference criteria for later stages of drug development. We tested pegolide and three antidepressants and two anticancer compounds on the ICESTP SAFETYPANEL^TM 77. The results demonstrated that our panel provides a competitive advantage by enabling the early identification of potential off-target ADRs and supporting informed decision-making, ultimately driving safer and more effective drug development.